ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO858

Liposomal Delivery Improves the Efficacy of Prednisolone to Reduce Renal Inflammation in a Mouse Model of Acute Renal Allograft Rejection

Session Information

  • Transplantation: Basic
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1801 Transplantation: Basic

Authors

  • van Alem, Carla, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Martina, Schmidbauer, Hannover Medical School, Hannover, Germany
  • Rong, Song, Hannover Medical School, Hannover, Germany
  • Braesen, Jan H., Hannover Medical School, Hannover, Germany
  • Thorenz, Anja, Hannover Medical School, Hannover, Germany
  • Chen, Rongjun, Hannover Medical School, Hannover, Germany
  • Ruben, Jurjen, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Winter, Elizabeth Martha, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Schilperoort, Maaike, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Kooijman, Sander, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Lalai, Reshma, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Metselaar, Josbert, Enceladus Pharmaceuticals, Naarden, Netherlands
  • Klemann, Christian, Hannover Medical School, Hannover, Germany
  • Meier, Martin, Hannover Medical School, Hannover, Germany
  • van Kooten, Cees, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
  • Gueler, Faikah, Hannover Medical School, Hannover, Germany
  • Rotmans, Joris I., Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
Background

Allograft rejection remains one of the main obstacles in kidney transplantation. Although treatment with high doses of corticosteroids is often efficacious, systemic exposure and activation of the glucocorticoid receptor (GR) results in substantial side effects. In this study we used a mouse model of acute renal allograft rejection to investigate whether liposomal encapsulation could facilitate local delivery of prednisolone to the allograft and enhance its therapeutic effect.

Methods

Male BalbCHanZtm recipients received a kidney transplant from male C57BL/6JHanZtm donors (n=10 per group). Recipients were injected daily with 5 mg/kg cyclosporine A and received either 10 mg/kg prednisolone (P), or liposomal prednisolone (LP) intravenously on day 0, 3, and 6, or no additional treatment (NA). Functional MRI was performed at day 6 (N=6) to study graft perfusion and organs were harvested at day 7 for FACS- and qPCR analysis.

Results

MRI analysis revealed better allograft perfusion upon LP treatment, as compared to NA treatment (428.3±114 vs 218.5±117 ml/min*100g, p<0.05) while P vs NA treatment showed no significant improvement. FACS analyses of allografts revealed a reduced number of CD45+ leukocytes in LP vs P or NA treatment (5,3 and 6,6 fold decrease, p<0.05), less CD3+ T cells in LP vs NA (3,7 fold decrease, p<0.05), and less F4/80+ macrophages in LP vs P and NA (4,3 and 4,2 fold decrease, p<0.05). Upon LP treatment, the expression of the GR responsive gene Fkbp5 was upregulated in the allograft, as compared to P and NA treatment (3,7 and 4,4 fold change, p<0.05).This was also observed in the spleen, but not in the heart, a non-target organ.

Conclusion

Liposomal delivery results in a higher local bioavailability of prednisolone, increased perfusion and a reduced cellular infiltrate in the transplanted kidney, compared to conventional prednisolone. Future clinical studies should reveal if treatment with LP results in improved efficacy and reduced side effects in patients with renal allograft rejection.

Funding

  • Commercial Support